ROCKET PHARMACEUTICALS, INC. financial data

Symbol
RCKT, RCKTW on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 802% % 1.4%
Debt-to-equity 16% % 1.5%
Return On Equity -62% % 0.29%
Return On Assets -54% % 0.48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 108,222,228 shares 19%
Common Stock, Shares, Outstanding 108,208,643 shares 19%
Entity Public Float $1,400,000,000 USD 17%
Common Stock, Value, Issued $1,082,000 USD 19%
Weighted Average Number of Shares Outstanding, Basic 111,571,136 shares 18%
Weighted Average Number of Shares Outstanding, Diluted 111,571,136 shares 18%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $150,025,000 USD -15%
General and Administrative Expense $97,154,000 USD -1%
Operating Income (Loss) $250,478,000 USD 8.5%
Net Income (Loss) Attributable to Parent $240,912,000 USD 6.7%
Earnings Per Share, Basic -2 USD/shares 18%
Earnings Per Share, Diluted -2 USD/shares 18%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $75,948,000 USD 16%
Cash, Cash Equivalents, and Short-term Investments $222,800,000 USD -5.5%
Assets, Current $227,680,000 USD -5.8%
Property, Plant and Equipment, Net $29,768,000 USD -23%
Operating Lease, Right-of-Use Asset $3,653,000 USD -16%
Intangible Assets, Net (Excluding Goodwill) $25,150,000 USD 0%
Goodwill $39,154,000 USD 0%
Assets $368,033,000 USD -6.5%
Employee-related Liabilities, Current $11,429,000 USD 11%
Liabilities, Current $31,170,000 USD -22%
Operating Lease, Liability, Noncurrent $2,758,000 USD -19%
Other Liabilities, Noncurrent $1,061,000 USD -7.1%
Liabilities $54,364,000 USD -15%
Accumulated Other Comprehensive Income (Loss), Net of Tax $9,000 USD -104%
Retained Earnings (Accumulated Deficit) $1,398,701,000 USD -21%
Stockholders' Equity Attributable to Parent $313,669,000 USD -4.9%
Liabilities and Equity $368,033,000 USD -6.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $55,790,000 USD 1.9%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $58,035,000 USD -266%
Common Stock, Shares Authorized 180,000,000 shares 0%
Common Stock, Shares, Issued 108,208,643 shares 19%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $77,313,000 USD 15%
Deferred Tax Assets, Valuation Allowance $129,077,000 USD 19%
Operating Lease, Liability $3,773,000 USD -15%
Payments to Acquire Property, Plant, and Equipment $364,000 USD -82%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $241,134,000 USD 6.3%
Lessee, Operating Lease, Liability, to be Paid $4,957,000 USD -17%
Property, Plant and Equipment, Gross $57,213,000 USD -1.3%
Operating Lease, Liability, Current $1,015,000 USD 1%
Lessee, Operating Lease, Liability, to be Paid, Year Two $759,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,005,000 USD 0.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,184,000 USD -23%
Lessee, Operating Lease, Liability, to be Paid, Year Three $522,000 USD -31%
Deferred Tax Assets, Operating Loss Carryforwards $67,591,000 USD 49%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $539,000 USD 3.3%
Operating Lease, Payments $364,000 USD 9.3%
Additional Paid in Capital $1,711,297,000 USD 15%
Depreciation, Depletion and Amortization $2,700,000 USD 42%
Share-based Payment Arrangement, Expense $42,035,000 USD -1.7%
Interest Expense $1,891,000 USD 0.42%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%